Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors-Reference-Cited by-同舟云学术

Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors

Published:2016-12-16 Issue:1 Volume:34 Page:90-94
ISSN:0736-8046
Container-title:Pediatric Dermatology
language:en
Short-container-title:Pediatr Dermatol

Author:

Boull Christina¹,Hook Kristen¹,Moertel Christopher²,Maguiness Sheilagh¹

Affiliation:

1. Division of Pediatric Dermatology; Department of Dermatology; University of Minnesota; Minneapolis Minnesota

2. Department of Pediatric Hematology/Oncology; University of Minnesota; Minneapolis Minnesota

Publisher

Wiley

Subject

Dermatology,Pediatrics, Perinatology, and Child Health

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/pde.13038/fullpdf

Reference11 articles.

1. The clinical development of MEK inhibitors;Zhao;Nat Rev Clin Oncol,2014

2. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC);Blumenschein;Ann Oncol,2015

3. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor;Kim;J Clin Oncol,2013

4. National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS. May 29, 2009 NIH publication 09-7473 http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf

5. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations;Flaherty;N Engl J Med,2012

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning‐Feuerstein‐Mims syndrome;Pediatric Dermatology;2024-01-25

2. Adverse cutaneous reactions associated with MEK inhibitor therapy in a pediatric population;Journal of the American Academy of Dermatology;2023-11

3. MEK inhibitor‐induced paronychia in a paediatric population: A tertiary centre experience;Australasian Journal of Dermatology;2023-05-24

4. Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option;Neuropediatrics;2021-12-14

5. Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review;Pediatric Blood & Cancer;2021-09-26